- ANGLE, the specialist medtech company with pioneering products for cancer diagnostics, has appointed Daniel Costin Danila, MD, as a scientific adviser to the company with immediate effect.

Danila is a leader in the development and adoption of CTCs as predictive biomarkers to help clinicians select appropriate treatments.

He is an assistant attending physician at Memorial Hospital Cancer Center in New York as well as an instructor with the Weill Cornell Medical College.

Danila's primary research focuses on prostate cancer.

Specifically, he is exploring a hypothesis that molecular profiling of circulating tumour cells (CTCs) can be used to assess biological determinants of the growth of prostate cancer tumours.

Story provided by